Back

Viability of engineered AAVs via protein language models

Desrosiers, M.; Ocari, T.; Trinquier, J.; Zin, E. A.; Van Meter, T.; Delmas, M.; Tekinsoy, M.; Planul, A.; Nemoto, T.; Dalkara, D.; Ferrari, U.

2026-06-11 bioinformatics
10.64898/2026.06.11.731521 bioRxiv
Show abstract

Capsid engineering has greatly improved the performance of recombinant AAV vectors used for gene therapy. One commonly used strategy is the insertion of a short, 7-mer, peptide into surface-exposed loops to modify receptor interactions and enhance cell entry. While effective in receptor retargeting and improved transduction, these insertions might destabilize the capsid protein, hinder assembly, and thus limit production. While previous attempts have used deep mutational scanning and AI to predict which insertions are viable, there is lack in understanding the structural consequences of these peptide insertions at the amino-acid level. Here we combined experiments, deep sequencing and large protein language models to gain insight on the impact of 7-mer insertions on the VR-VIII region. We first characterize the biochemical properties of viable insertions, thus identifying which residues are well tolerated, and which should instead be avoided. We then focus on the nearby context of those insertions, by studying the effect of the linkers, either for highly diverse libraries or for individual variants known for their efficiency. Next, we study the broader context, by extending our analysis to the whole capsid sequence, and identifying regions that can tolerate insertions without long-ranged structural deformations that could affect capsid functionality. We conclude with a cross-serotype comparison and a viability analysis of tens of previously engineered variants. Our work showcases how AI can uncover structure-function rules governing the success of engineered AAV capsids.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
PLOS Computational Biology
1863 papers in training set
Top 2%
15.0%
2
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.1%
9.6%
3
Scientific Reports
3612 papers in training set
Top 11%
6.7%
4
Nature Communications
5641 papers in training set
Top 27%
5.5%
5
Nucleic Acids Research
1281 papers in training set
Top 4%
4.8%
6
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.2%
4.8%
7
iScience
1154 papers in training set
Top 4%
4.3%
50% of probability mass above
8
Journal of Virology
499 papers in training set
Top 2%
3.2%
9
mAbs
32 papers in training set
Top 0.2%
2.8%
10
Science Advances
1243 papers in training set
Top 13%
2.6%
11
Cell Systems
201 papers in training set
Top 2%
2.4%
12
PLOS ONE
5266 papers in training set
Top 42%
2.4%
13
Biophysical Journal
631 papers in training set
Top 3%
2.1%
14
Virus Evolution
155 papers in training set
Top 0.7%
2.1%
15
Molecular Systems Biology
162 papers in training set
Top 1%
2.1%
16
ACS Synthetic Biology
287 papers in training set
Top 1%
2.1%
17
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 28%
1.7%
18
eLife
5828 papers in training set
Top 52%
1.5%
19
Molecular Therapy
81 papers in training set
Top 1%
1.5%
20
PLOS Pathogens
820 papers in training set
Top 7%
1.4%
21
Frontiers in Immunology
638 papers in training set
Top 7%
1.3%
22
Communications Biology
993 papers in training set
Top 22%
1.1%
23
Bioinformatics
1204 papers in training set
Top 8%
1.1%
24
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 3%
0.8%
25
Nature Biotechnology
172 papers in training set
Top 4%
0.8%
26
Acta Crystallographica Section D Structural Biology
59 papers in training set
Top 0.5%
0.8%
27
Cell Reports Methods
165 papers in training set
Top 5%
0.6%
28
Protein Science
246 papers in training set
Top 4%
0.6%
29
Molecular Therapy Methods & Clinical Development
13 papers in training set
Top 0.2%
0.6%
30
JCI Insight
277 papers in training set
Top 9%
0.6%